Courses
ATU iHub client company CroíValve secures €33 million Series B investment
CroíValve, a Dublin-based medical technology company with a research office at the iHub in Atlantic Technological University (ATU), Galway, has secured €33 million in a Series B funding round
This significant investment will support the continued development and clinical advancement of the company’s innovative cardiovascular therapies. The Irish medtech company is developing a minimally invasive treatment for tricuspid regurgitation, a serious heart condition affecting millions globally.
ATU iHub Manager Turlough Rafferty congratulated the company on securing $36 million (approximately €33 million) in Series B funding.
It marks a significant milestone in its growth. The round includes a $20 million (€18.4 million) expansion, alongside $7 million (€6.4 million) in grant funding, bringing total funding linked to the round to $43 million (approximately €39.5 million) including grants. The investment, backed by BGF, the European Innovation Council and the MedTech Syndicate, will support the expansion of CroíValve’s TANDEM II clinical trial across the US and Europe.
CroíValve’s DUO™ system offers a non-surgical option for patients unsuitable for traditional procedures, aiming to improve outcomes for those living with this complex condition.
ATU iHub supports entrepreneurs, start-ups, and scaling companies through incubation, innovation programmes, and access to a dynamic network across Ireland’s west and northwest. The iHub is committed to enabling businesses to grow, scale, and achieve global impact. CroíValve is an Irish clinical-stage medical device company focused on developing innovative, minimally invasive solutions to treat tricuspid regurgitation, a serious and often overlooked heart condition. Its proprietary DUO™ system is designed to restore valve function without the need for open-heart surgery, improving outcomes for patients who are unsuitable for conventional treatments. With operations spanning Ireland and the United States, CroíValve is advancing clinical studies to bring its breakthrough technology to patients worldwide.
Picture caption: Professor Grygier (in blue), Poznan University of Medical Sciences team, pictured with the CroíValve team.
For media enquiries, contact:
Regina Daly
Communications and Press Officer
Tel: 087 961 8355
E: regina.daly@atu.ie
